Edition:
United Kingdom

People: Dynavax Technologies Corp (DVAX.OQ)

DVAX.OQ on NASDAQ Stock Exchange Capital Market

3.97USD
18 Jun 2019
Change (% chg)

$-0.13 (-3.17%)
Prev Close
$4.10
Open
$4.11
Day's High
$4.20
Day's Low
$3.95
Volume
299,333
Avg. Vol
312,732
52-wk High
$16.30
52-wk Low
$3.58

Janssen, Robert 

Dr. Robert Janssen, M.D., serves as Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory Affairs of Dynavax Technologies Corporation. Dr. Janssen was appointed Chief Medical Officer and Senior Vice President, Clinical Development, Medical and Regulatory Affairs in January 2018. Dr. Janssen was appointed Chief Medical Officer and Vice President, Clinical Development and Regulatory Affairs in July 2013. He served as Dynavax’s Vice President, Medical Affairs since November 2012 and was previously Senior Director, Clinical Development at Dynavax from 2010 through 2012, during which time he was extensively involved with Phase 3 clinical development of HEPLISAV-B and its U.S. and European licensing applications. Prior to joining Dynavax, Dr. Janssen was Vice President, Medical Affairs at Gilead from 2008 to 2010 where he was responsible for oversight of physician and health care provider education focused on HIV and hepatitis B therapies. Until 2008, Dr. Janssen spent 23 years at the U.S. Centers for Disease Control and Prevention (“CDC”), most recently as the Director of the Division of HIV/AIDS Prevention from 2000 to 2008. Under his leadership, the CDC first explored HIV treatment as a mode of HIV prevention and launched several of the earliest Phase 3 trials of pre-exposure prophylaxis for HIV. Dr. Janssen received a Bachelor of Arts degree with Honors in Humanities from Stanford University and his M.D. degree from the University of Southern California. He is a neurologist with training in virology received at the University of Pennsylvania. Dr. Janssen has been the beneficiary of numerous honors and awards during his career. He has published over 130 scientific articles in a variety of journals and has served as a reviewer for leading scientific journals.

Basic Compensation

Total Annual Compensation, USD 438,000
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 1,301,810
Fiscal Year Total, USD 1,739,810

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Arnold Oronsky

231,767

David Novack

1,697,590

Ryan Spencer

--

Eddie Gray

4,748,840

Michael Ostrach

3,562,510

Robert Coffman

3,628,280
As Of  31 Dec 2018